uncommon but severe problem, especially in elderly patients and those with coagulopathy. Chitosan-based hemostatic dressings have offered safe and effective solutions for numerous hemorrhagic conditions. The present study assessed the feasibility and safety of a hemostatic catheter device with a chitosan endoluminal hemostatic dressing (CEHD) that is able to control and prevent prostatic bleeding via transurethral application.
INTRODUCTION AND OBJECTIVES: Holmium laser enucleation of the prostate (HoLEP) was developed as an effective and minimally invasive alternative to traditional surgical techniques. Since its introduction in the late 1990s, HoLEP has shown equal or better outcomes than TURP or OP, with a lower risk of intraoperative bleeding and blood transfusion. These results have been confirmed in patients receiving anticoagulant/ antithrombotic therapy. However, due to the prolonged learning curve of the technique, HoLEP has barely entered the urological community, thus limiting the data available on the daily use of this technique. One of the unmet needs regarding the use of HoLEP for BPH is the identification of factors influencing intraoperative blood loss. The objective of this work is to assess blood loss during holmium laser enucleation of the prostate (HoLEP) and investigate the factors influencing it.
METHODS: Retrospective analysis of patients with benign prostatic hyperplasia (BPH) treated with HoLEP at three centres. Haemoglobin and haematocrit were measured before surgery and hospital discharge. All blood transfusions performed during and after HoLEP were recorded. Blood loss outcomes were analysed in relation to antithrombotic (antiplatelet/anticoagulant) therapies and drug treatments for BPH.
RESULTS: The analysis included 963 patients with a mean age of 72 years. Mean (range) prostate size was 102 (40-316) g; 28% of patients were receiving antiaggregants and 11% anticoagulants. Mean (range) prostate-specific antigen was 6.0 (0.3-43.5) ng/dL. Mean (range) operation time was 77 (28-178) min. Bladder calculi were found in 54 (5.6%) patients; all of them were successfully treated with cystolitholapaxy. Forty-eight (5%) patients required blood transfusion during or immediately after the HoLEP procedure. Overall, mean (SD) haemoglobin decreased from 14.6 (1.5) g/dL to 12.3 (2.1) g/dL (p<0.001), and mean (SD) haematocrit decreased from 44.3% (4.7) to 37.7% (6.5) (p<0.001). Neither haemoglobin nor haematocrit decreases were significantly different between patients receiving and not receiving antithrombotic therapy or BPH therapy.
CONCLUSIONS: HoLEP is a safe procedure with no remarkable concerns regarding blood loss, including patients at high risk, such as those receiving antithrombotic therapy. Operating time may influence haemoglobin decrease and, therefore, it should be considered in patients with higher risk of bleeding.
Source of Funding: none

MP45-15 EVALUATION OF SEXUAL FUNCTION AFTER THULIUM LASER ENUCLEATION OF PROSTATE
Mohammad Shohrab Hossain*, Mohammad Fazal Naser, Mohammad Rabiul Islam, Dhaka, Bangladesh INTRODUCTION AND OBJECTIVES: Introduction: The effect of currently available surgical procedures for BPH on erection and ejaculation has been poorly studied. This study aim to assess the effect of thulium laser enucleation of prostate (ThuLEP) on sexual function and retrograde ejaculation in patient with BPH. We performed a prospective study on 50 consecutive patients who have undergone Thu-LEP and analyse the changes in urinary symptoms and sexual function by 4 validated questionnaire: ICIQ-LUTSqol Module, MSHQ-Ejd, IIEF-5, IPSS. Patient also underwent uroflowmetry to assess urinary flow and were followed up 6 months after ThuLEP. Objective: To assess the effect of Thulium laser enucleation of prostate (ThuLEP) on sexual function and retrograde ejaculation and quality of life in patients with BPH, as well as safety of the procedure METHODS: Between January 2016 to June 2018, we have done fifty consecutive thulium laser enucleation of prostate for BPH causing bladder outflow obstruction, confirmed by clinical examination and investigation and pre-operative sexual function was assessed by 4-validated questionnaire. All patients were selected prospectively as per selection and exclusion criteria. Enucleation was possible in all of the cases, with very minimal blood loss and short hospital stay. Normal saline was used for irrigation in all of the cases. Of the eleven patients, one patient developed retention of urine after removal of catheter. Mild dysuria was experienced by 2 patients. No blood transfusion was required in any patient. Significant improvement was observed in IPSS score and in USG & uroflowmetry.
RESULTS: Between January 2016 to June 2018, 50 cases age ranging from 55-75 years of BPH underwent ThuLEP, mean operation time was 50 minutes, catheterization period 24-48 hours and hospital stay 48 hours to 120 hours. During post operative period clot retention and haematuria did not occur and transfusion was not needed. All patients were followed up after operation and at 3 months and 6 months postoperatively, by urine analysis, uroflowmetry, ICIQ-LUTSqol Module, MSHQ-Ejd, IIEF-5, IPSS. ThuLEP was found to improve urinary flow and quality of life. 64% patients have conserved ejaculation and erectile function after ThuLEP, 12% reported painful ejaculation . No significant changes in the erectile function CONCLUSIONS: ThuLEP improves urinary flow and quality of life and conserve satisfactory sexual function in terms of erection and ejaculation
